Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
CP+ Analysis

Charles River's $470m Frontage Carve-Out Buys Bioanalysis Depth Through a Take-Private

Charles River will pay about $470m, plus up to $75m in performance payments, for Frontage's Exton bioanalysis and DMPK units. The deal needs a consortium to take the parent private first.

15 Nov 2026 · CompePharma editorial

What happened

Charles River Laboratories has signed definitive agreements to acquire Frontage's bioanalysis and drug metabolism and pharmacokinetics (DMPK) businesses in Exton, Pennsylvania, for about $470m. Up to $75m in further performance-based payments could follow. The structure is unusual: the transaction runs through a consortium arrangement that first takes Frontage private, so the Exton units reach Charles River only after the parent changes hands.

The material available does not specify the consortium's members, the closing timetable, or the financial profile of the Exton units. Those are the first things to establish. The headline price and the earn-out are the only hard numbers, and the earn-out matters for what it signals, covered below.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Sources

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.

More CP+ AnalysisAll →